Plum SEC
  • Korean Market
  • Community
  • Contact Us

Korean Market

  • Reset (View All)

  • ★★★★★
  • ★★★★
  • ★★★
  • ★★
  • ★

  • ★

  • ★
  • ★★
  • ★★★
  • ★★★★
  • ★★★★★
AI Disclosures
EXCH
Daewoong Pharma
★★
Daewoong Pharma Enters Technology Introduction Contract for Semaglutide Long-Acting Injectable (Conditional, Amount Undisclosed)
 8h ago
EXCH
Daewoong Pharma
★★
Completion of Licensor Succession for mRNA-based ERA Platform Technology Transfer Agreement (Total USD 239M)
 05/20/2026, 05:54 PM
PERI
Daewoong Pharma
★
Daewoong Pharmaceutical 2026 Q1: Revenue Growth Continues, Operating Profit Declines, New Technology Acquisition and Pipeline Strength
 05/15/2026, 03:46 PM
EXCH
Daewoong Pharma
★★
Technology Introduction Contract Signed for INV-008 (15-PGDH Inhibitor)
 05/12/2026, 05:40 PM
EXCH
Daewoong Pharma
★★
Q1 2026 Preliminary Results: Operating Profit Down, Net Income Up
 05/12/2026, 03:48 PM
EXCH
Daewoong Pharma
★★
Assumption of Licensor Position in mRNA-based ERA Technology (Contract with HanAll BioPharma)
 05/07/2026, 04:55 PM
EXCH
Daewoong Pharma
★★★★
Fexuclue Gets Additional Indication for H. pylori Eradication
 05/03/2026, 07:00 AM
  • «
  • 1
  • »
한국어 | English | 中文 | 日本語
Plum SEC © 2026.05.25
The information provided on this site is for reference only and we do not guarantee its accuracy or completeness. Users are solely responsible for any investment decisions made based on this information.